Pharmacognosy intro
Cedrus atlantica (Endl.) Manetti ex Carriere (Pinaceae) and Juniperus virginiana L. (Cupressaceae) are the two primary botanical sources sold as cedarwood essential oil, though they belong to different families with significantly different chemistry. Atlas cedar is a true cedar; Virginia cedar is a juniper. The essential oil is steam-distilled from heartwood and wood shavings. Common names include cedarwood, Atlas cedar, Virginia cedar, and red cedar. The heartwood of Cedrus deodara ("wood of the gods") is used in Ayurvedic medicine, while Juniperus virginiana holds ceremonial significance in Native American traditions. The dominant bioactive constituent is cedrol, an oxygenated sesquiterpene present at 13-25% concentration. Cedrol enhances parasympathetic nervous system activity while simultaneously reducing sympathetic output, producing measurable sedative and anxiolytic effects. Additional sesquiterpene hydrocarbons include alpha-cedrene (6-18%, antifungal, insecticidal), thujopsene (10-31%, antiproliferative against cancer cell lines, insect repellent), and widdrol (9-12%, antifungal, anti-termitic). Himachalene, characteristic of Atlas cedar specifically, provides anti-inflammatory activity. 8,14-Cedranoxide (7-8%) contributes woody-amber facets to the aroma profile. Clinical research on cedrol's autonomic effects is supported by Jiang et al. (2018, IEEJ Transactions), who confirmed that cedrol inhalation induces a significant increase in parasympathetic nervous system activity with a concomitant reduction in sympathetic activity. Xu et al. (2024, BioFactors) demonstrated that cedrol enhances ATP content and intestinal epithelial barrier integrity, upregulates tight junction protein expression (ZO-1, Occludin, Claudin-1), and restores metabolomic profiles disrupted by inflammatory challenge. A critical safety finding from Zehetner et al. (2019, Flavour and Fragrance Journal) established that cedrol, beta-cedrene, and thujopsene markedly inhibit CYP2B6-mediated metabolism (comparable to thioTEPA) and significantly block CYP3A4-mediated reactions. This creates meaningful drug interaction potential with antiretrovirals (efavirenz), anticancer agents (cyclophosphamide, ifosfamide), antidepressants (bupropion), statins (atorvastatin, simvastatin), calcium channel blockers (amlodipine, nifedipine), immunosuppressants (cyclosporine, tacrolimus), and macrolide antibiotics (clarithromycin). Toxicity is low: LD50 exceeds 5.00 g/kg (oral, rat), classified as not toxic. Internal use is not recommended.